PDF(Pubmed)
Abstract：
Τhis study aims to assess changes in the fovea avascular zone (FAZ) in treatment naïve patients receiving aflibercept or ranibizumab injections for diabetic macular edema (DME). Best corrected visual acuity (BCVA) testing, OCT, and OCT-angiography imaging were performed at baseline and 1 month after each injection. Injections of either aflibercept or ranibizumab were administered monthly for 6 consecutive months. FAZ in the superficial (SCP) and the deep capillary plexus (DCP) using OCT angiography was recorded for each visit. Fifty eyes from fifty patients with a mean age of 67.0 ± 10.7 years were included in the study. Twenty-five patients received aflibercept and twenty-five received ranibizumab. BCVA was 40.8 ± 10.0 and increased to 52.1 ± 7.9 ETDRS letters at the last visit (p < 0.001). CRT was 295.6 ± 34.0 at baseline and 247.9 ± 29.7 at the last study visit (p < 0.001). SCP FAZ was 350.6 ± 79.5 μm2 at baseline and 339.0 ± 71.3 μm2 after sox monthly injections (p = 0.132). DCP FAZ was 558.6 ± 199.0 μm2 at baseline and 459.5 ± 156.1 μm2 after six monthly injections (p < 0.001). There was no effect of the choice of ranibizumab or aflibercept on DCP FAZ change (p = 0.277). In conclusion, treatment with 6 monthly injections of ranibizumab and aflibercept led to an increase in BCVA and a decrease in CRT and DCP FAZ area. Both drugs led to an improvement in DCP ischemia.
摘要：
该研究旨在评估接受阿柏西普或雷珠单抗注射治疗糖尿病性黄斑水肿（DME）的初治患者的中央凹无血管区（FAZ）的变化。最佳矫正视力（BCVA）测试，OCT,在基线和每次注射后1个月进行OCT-血管造影成像.每月连续6个月注射阿柏西普或雷珠单抗。每次就诊时使用OCT血管造影记录浅表（SCP）和深毛细血管丛（DCP）的FAZ。该研究包括50名平均年龄为67.0±10.7岁的患者的50只眼。25例患者接受阿柏西普治疗，25例患者接受雷珠单抗治疗。BCVA为40.8±10.0，在最后一次访问时增加到52.1±7.9ETDRS字母（p<0.001）。基线时的CRT为295.6±34.0，最后一次随访时的CRT为247.9±29.7（p<0.001）。SCPFAZ在基线时为350.6±79.5μm2，在每月注射sox后为339.0±71.3μm2（p=0.132）。DCPFAZ在基线时为558.6±199.0μm2,在6个月注射后为459.5±156.1μm2(p<0.001)。选择雷珠单抗或阿柏西普对DCPFAZ变化没有影响(p=0.277)。总之,每月6次注射雷珠单抗和阿柏西普治疗导致BCVA增加,CRT和DCPFAZ面积减少.两种药物均导致DCP缺血的改善。
